29 June 2022 - TAs 799 and 800 are for the same technology.

Faricimab is recommended as an option for treating visual impairment due to diabetic macular oedema in adults, only if:

• the eye has a central retinal thickness of 400 micrometres or more at the start of treatment
• Roche provides faricimab according to the commercial arrangement.

Faricimab is recommended as an option for treating wet age-related macular degeneration in adults, only if:

• the eye has a best-corrected visual acuity between 6/12 and 6/96
• there is no permanent structural damage to the central fovea
• the lesion size is 12 disc areas or less in greatest linear dimension
• there are signs of recent disease progression (for example, blood vessel growth as shown by fluorescein angiography, or recent visual acuity changes)
• Roche provides faricimab according to the commercial arrangement.

Read NICE TA799

Read NICE TA800